We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout
Read MoreHide Full Article
Shares of small-biotech Mereo BioPharma (MREO - Free Report) surged 62.5% on Jun 17, following a report issued by the Times, which stated that AstraZeneca (AZN - Free Report) is interested in acquiring the company. Mereo BioPharma is a U.K.-based pharmaceutical company focused on developing therapies targeting cancer and rare diseases.
Per the article, Mereo is in discussions with AstraZeneca to accept the bid at $5 per share, amounting to a total purchase price of nearly $500 million.
In the year so far, shares of Mereo have fallen 18.8% compared with the industry’s decline of 28.1%.
Mereo has an existing partnership with AstraZeneca. AZN and MREO have a license agreement whereby the latter acquired exclusive worldwide rights for alvelestat, a rare-disease product candidate initially discovered by AstraZeneca. The candidate is currently being developed by Mereo for alpha-1-anti-trypsin deficiency (AATD) and bronchiolitis obliterans syndrome (BOS).
Per the terms of the agreement, Mereo has also been granted an option to acquire the candidate as well. In return, AstraZeneca is eligible to receive potential milestone payments. MREO is currently conducting clinical studies, evaluating alvelestat in separate mid-stage studies, across both AATD and BOS.
AstraZeneca is highly focused on strengthening its oncology business. In first-quarter 2022, AZN’s Oncology business generated $3.6 billion worth of total revenues, reflecting a 25% year-over-year rise at constant exchange rates, driven by the solid performance of newer medicines, such as Tagrisso, Lynparza, Imfinzi and Calquence. AZN is working to further strengthen its portfolio through label expansions and advancing oncology pipeline candidates.
The article also suggests that if AstraZeneca confirms this buyout offer, then it may face stiff competition from Mereo’s other partners who may also be interested in making an acquisition offer, including companies like Ultragenyx Pharmaceutical (RARE - Free Report) and OncXerna.
Mereo has a partnership with Ultragenyx to develop setrusumab, another rare-disease product candidate, being developed as a potential treatment for Osteogenesis Imperfecta (“OI”). In April 2022, Ultragenyx dosed the first patient in a pivotal phase II/III study, evaluating setrusumab for treating OI in patients aged between five and less than 26 years. RARE expects to initiate a phase II study evaluating the drug in OI patients aged between 2 and 5 years later this year.
Mereo’s lead oncology candidate is etigilimab, a TIGIT inhibitor, being developed in a phase Ib/II study in combination with Bristol Myers‘ (BMY - Free Report) PD-1 inhibitor, Opdivo (nivolumab), in a range of tumor types, including three rare tumors and three gynecological carcinomas, cervical, ovarian, and endometrial carcinomas.
Opdivo is one of the many blockbuster drugs marketed by Bristol Myers. The drug is approved for multiple oncology indications. The drug is a key top-line driver for BMY. In first-quarter 2022, Bristol Myers generated $1.9 billion from Opdivo sales.
On May 23, 2022, Mereo was notified by NASDAQ that it faces the risk of delisting of its ADRs, after it failed to maintain the minimum price of $1 over the previous 30 business days. The stock exchange has requested MREO to resume compliance with this rule by Nov 21. A positive confirmation of this buyout offer is expected to not only benefit Mereo but also its current shareholder base.
Image: Bigstock
Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout
Shares of small-biotech Mereo BioPharma (MREO - Free Report) surged 62.5% on Jun 17, following a report issued by the Times, which stated that AstraZeneca (AZN - Free Report) is interested in acquiring the company. Mereo BioPharma is a U.K.-based pharmaceutical company focused on developing therapies targeting cancer and rare diseases.
Per the article, Mereo is in discussions with AstraZeneca to accept the bid at $5 per share, amounting to a total purchase price of nearly $500 million.
In the year so far, shares of Mereo have fallen 18.8% compared with the industry’s decline of 28.1%.
MEREO BIOPHARMA Price
MEREO BIOPHARMA price | MEREO BIOPHARMA Quote
Mereo has an existing partnership with AstraZeneca. AZN and MREO have a license agreement whereby the latter acquired exclusive worldwide rights for alvelestat, a rare-disease product candidate initially discovered by AstraZeneca. The candidate is currently being developed by Mereo for alpha-1-anti-trypsin deficiency (AATD) and bronchiolitis obliterans syndrome (BOS).
Per the terms of the agreement, Mereo has also been granted an option to acquire the candidate as well. In return, AstraZeneca is eligible to receive potential milestone payments. MREO is currently conducting clinical studies, evaluating alvelestat in separate mid-stage studies, across both AATD and BOS.
AstraZeneca is highly focused on strengthening its oncology business. In first-quarter 2022, AZN’s Oncology business generated $3.6 billion worth of total revenues, reflecting a 25% year-over-year rise at constant exchange rates, driven by the solid performance of newer medicines, such as Tagrisso, Lynparza, Imfinzi and Calquence. AZN is working to further strengthen its portfolio through label expansions and advancing oncology pipeline candidates.
The article also suggests that if AstraZeneca confirms this buyout offer, then it may face stiff competition from Mereo’s other partners who may also be interested in making an acquisition offer, including companies like Ultragenyx Pharmaceutical (RARE - Free Report) and OncXerna.
Mereo has a partnership with Ultragenyx to develop setrusumab, another rare-disease product candidate, being developed as a potential treatment for Osteogenesis Imperfecta (“OI”). In April 2022, Ultragenyx dosed the first patient in a pivotal phase II/III study, evaluating setrusumab for treating OI in patients aged between five and less than 26 years. RARE expects to initiate a phase II study evaluating the drug in OI patients aged between 2 and 5 years later this year.
Mereo’s lead oncology candidate is etigilimab, a TIGIT inhibitor, being developed in a phase Ib/II study in combination with Bristol Myers‘ (BMY - Free Report) PD-1 inhibitor, Opdivo (nivolumab), in a range of tumor types, including three rare tumors and three gynecological carcinomas, cervical, ovarian, and endometrial carcinomas.
Opdivo is one of the many blockbuster drugs marketed by Bristol Myers. The drug is approved for multiple oncology indications. The drug is a key top-line driver for BMY. In first-quarter 2022, Bristol Myers generated $1.9 billion from Opdivo sales.
On May 23, 2022, Mereo was notified by NASDAQ that it faces the risk of delisting of its ADRs, after it failed to maintain the minimum price of $1 over the previous 30 business days. The stock exchange has requested MREO to resume compliance with this rule by Nov 21. A positive confirmation of this buyout offer is expected to not only benefit Mereo but also its current shareholder base.
Zacks Rank
Mereo BioPharma currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.